- Home
- RCON vs APLT Comparison
RCON vs APLT Comparison
Compare RCON & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCON
- APLT
- Stock Information
- Founded
- RCON 2007
- APLT 2016
- Country
- RCON China
- APLT United States
- Employees
- RCON N/A
- APLT N/A
- Industry
- RCON Oilfield Services/Equipment
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- RCON Energy
- APLT Health Care
- Exchange
- RCON Nasdaq
- APLT Nasdaq
- Market Cap
- RCON 45.3M
- APLT 37.5M
- IPO Year
- RCON 2009
- APLT 2019
- Fundamental
- Price
- RCON $2.08
- APLT $0.35
- Analyst Decision
- RCON
- APLT Buy
- Analyst Count
- RCON 0
- APLT 7
- Target Price
- RCON N/A
- APLT $6.10
- AVG Volume (30 Days)
- RCON 19.3K
- APLT 2.9M
- Earning Date
- RCON 06-27-2025
- APLT 05-13-2025
- Dividend Yield
- RCON N/A
- APLT N/A
- EPS Growth
- RCON N/A
- APLT N/A
- EPS
- RCON N/A
- APLT N/A
- Revenue
- RCON $8,996,572.00
- APLT $265,000.00
- Revenue This Year
- RCON N/A
- APLT $1,768.13
- Revenue Next Year
- RCON $12.17
- APLT $332.85
- P/E Ratio
- RCON N/A
- APLT N/A
- Revenue Growth
- RCON N/A
- APLT N/A
- 52 Week Low
- RCON $1.32
- APLT $0.30
- 52 Week High
- RCON $3.70
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- RCON 52.90
- APLT 41.78
- Support Level
- RCON $1.90
- APLT $0.37
- Resistance Level
- RCON $2.39
- APLT $0.40
- Average True Range (ATR)
- RCON 0.18
- APLT 0.06
- MACD
- RCON 0.02
- APLT -0.01
- Stochastic Oscillator
- RCON 42.13
- APLT 2.00
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.